TRIPHASE
Not Specified
Phase 0Active
Key Facts
About TRACER Europe
TRACER Europe is a pioneering imaging CRO that leverages Phase 0 microdosing and molecular imaging to de-risk and accelerate drug development for biopharma sponsors. Its core service involves labeling a sponsor's drug candidate (antibody, small molecule, peptide, etc.) to visualize and quantify its behavior in human patients at a very early stage, enabling critical go/no-go decisions before costly traditional trials. Founded in 2018, the private company operates in a high-growth niche, helping clients reduce development costs and timelines by providing human proof-of-concept data faster than conventional pathways.
View full company profileTherapeutic Areas
Other Not Specified Drugs
| Drug | Company | Phase |
|---|---|---|
| New TCM Formulations | China SXT Pharmaceuticals | Research / Pre-clinical |
| Long-acting Leronlimab | CytoDyn | Preclinical |
| Collaborative Program with Ferring | PharmaBiome | Research |
| Lighthouse Pilot Product | Cipherome | Pilot |
| Nitric Oxide + Collagen Delivery | Jellagen | Research |
| Undisclosed | Authera | Pre-clinical |
| mRNA Therapeutics Platform Application | Lupagen | Research |
| PHYRAGO | Handa Pharmaceuticals | Approved |
| TASCENSO ODT | Handa Pharmaceuticals | Approved |
| Axulin | Housey Pharmaceutical Research Laboratories | Commercial |
| PBI-04711 | Phoenix Biotechnology | Pre-clinical |
| Immunology Program | Ignite Biomedical | Discovery |